Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
McKinsey
Dow
McKesson
Boehringer Ingelheim

Last Updated: January 21, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ACALABRUTINIB

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for Acalabrutinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02029443 ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia Active, not recruiting Acerta Pharma BV Phase 1/Phase 2 2014-01-01 This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
NCT02157324 Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia Active, not recruiting Acerta Pharma BV Phase 1 2014-08-01 This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
NCT02180711 An Open-label, Phase 1b Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma Active, not recruiting Acerta Pharma, LLC Phase 1 2014-07-01 To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with relapsed,refractory,or treatment naive Follicular Lymphoma (FL)
NCT02180711 An Open-label, Phase 1b Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma Active, not recruiting Acerta Pharma BV Phase 1 2014-07-01 To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with relapsed,refractory,or treatment naive Follicular Lymphoma (FL)
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Acalabrutinib

Condition Name

Condition Name for Acalabrutinib
Intervention Trials
Chronic Lymphocytic Leukemia 14
Mantle Cell Lymphoma 5
Small Lymphocytic Lymphoma 4
DLBCL 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Acalabrutinib
Intervention Trials
Lymphoma 20
Leukemia, Lymphoid 20
Leukemia, Lymphocytic, Chronic, B-Cell 20
Leukemia 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Acalabrutinib

Trials by Country

Trials by Country for Acalabrutinib
Location Trials
United States 94
United Kingdom 7
Canada 4
Spain 3
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Acalabrutinib
Location Trials
Ohio 10
Texas 9
Washington 8
New York 8
Florida 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Acalabrutinib

Clinical Trial Phase

Clinical Trial Phase for Acalabrutinib
Clinical Trial Phase Trials
Phase 3 9
Phase 2/Phase 3 1
Phase 2 22
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Acalabrutinib
Clinical Trial Phase Trials
Not yet recruiting 23
Recruiting 13
Active, not recruiting 9
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Acalabrutinib

Sponsor Name

Sponsor Name for Acalabrutinib
Sponsor Trials
Acerta Pharma BV 25
AstraZeneca 9
National Cancer Institute (NCI) 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Acalabrutinib
Sponsor Trials
Industry 40
Other 26
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Johnson and Johnson
Colorcon
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.